Alembic Pharma Board Meeting on Nov 4 to Approve Q2 FY27 Results

Alembic Pharmaceuticals Ltd has announced that its Board of Directors will convene on November 4, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. Additionally, the company will address the re-opening of the trading window for its securities, which will resume 48 hours after the declaration of these financial results. The trading window had been closed since October 1, 2026, in accordance with the company's code of conduct for designated persons.